Sientra Appoints Ron Menezes as President and Chief Executive Officer
November 09 2020 - 4:01PM
Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a global
medical aesthetics company, announced today that Ron Menezes,
former President and General Manager for Almirall Inc., will join
Sientra as President and Chief Executive Officer of Sientra, Inc.,
effective November 10, 2020. Jeffrey Nugent, the Company’s Chairman
and Chief Executive Officer since 2015, also announced his
retirement from his current responsibilities. He will remain with
Sientra through the end of the year in an advisory role to support
Mr. Menezes in the transition and to ensure continuity in carrying
out the Company’s long-term vision. Caroline Van Hove, current
Sientra Director, will expand her position on Sientra’s Board of
Directors and succeed Mr. Nugent as Executive Chair.
Mr. Nugent said, “It has been an honor to serve as Chairman and
Chief Executive Officer of Sientra over the last five years. In
that time, our team has overcome a succession of strategic and
executional challenges that, ultimately, made us into a stronger
category leader and a more competitive, credible provider and
partner to Sientra’s core plastic surgery customers. As I look to
focus on the other passions in my life, I am excited to work with
Ron over the next two months to further position Sientra for
long-term success.”
Mr. Menezes said, “This is an exciting time to join Sientra,
given the Company’s outstanding and sustained performance over the
last several years and the opportunity for me to lead a dynamic
team and build on this momentum to increase our category leadership
position, particularly Sientra’s core Breast Products business.
This business will serve as the foundation of our growth and I look
forward to building on the incredible progress the Company has made
as we move into the next phase of success for Sientra.”
Over nearly 30 years in the pharmaceuticals and aesthetics
industries, Mr. Menezes has shown to be a successful, driven
commercial leader with a track record of performance. Most
recently, he led Almirall’s U.S. dermatology division through an
impactful turnaround, returning it to profitability by
strategically lowering costs associated with product distribution
and reorganizing the company. Mr. Menezes was also a member of
Almirall’s Mergers & Acquisitions team that successfully
acquired Allergan’s dermatology assets in 2018. In 2019, he led the
launch of a new molecule for the treatment of acne that far
exceeded revenue goals by strategically focusing on improving
patients’ access to the product.
Ms. Van Hove said, “Jeff leaves Sientra with a firm foundation
in place, strong momentum and an increased focus on breast products
that will allow us to continue to deliver additional value for
stakeholders. Words cannot express what he has meant to our
emergence as a leader. We will miss Jeff’s leadership and constant
presence and look forward to Ron leading Sientra into a new chapter
of anticipated high growth.”
Ms. Van Hove brings deep expertise in medical aesthetics,
including breast aesthetics, and 20 years of global pharma and
medical device experience to Sientra’s Board of Directors, on which
she has served since January 2020. She is currently President and
CEO of a venture-backed, clinical-stage medical aesthetics company,
and previously held several commercial leadership roles at
Allergan.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a
diversified global medical aesthetics company and a leading partner
to aesthetic physicians. The Company offers a suite of products
designed to make a difference in patients' lives by enhancing their
body image, growing their self-esteem, and restoring their
confidence. Sientra has developed a broad portfolio of products
with technologically differentiated characteristics, supported by
independent laboratory testing and strong clinical trial outcomes.
The Company’s Breast Products Segment includes its OPUS® breast
implants, the first fifth generation breast implants approved by
the FDA for sale in the United States, its ground-breaking Allox2®
breast tissue expander with patented dual-port and integral drain
technology, and BIOCORNEUM® the #1 performing, preferred and
recommended scar gel of plastic surgeons(*). The Company’s miraDry
Segment, comprised of its miraDry® system, is approved for sale in
over 56 international markets and is the only non-surgical,
FDA-cleared device indicated for the permanent reduction of
underarm sweat and hair and may also reduce odor.
Sientra uses its investor relations website to publish important
information about the Company, including information that may be
deemed material to investors. Financial and other information about
Sientra is routinely posted and is accessible on the Company’s
investor relations website at www.sientra.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, based on management’s current assumptions and expectations
of future events and trends, which affect or may affect the
Company’s business, strategy, operations or financial performance,
and actual results may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are made only as of the date of this
release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’
‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’
‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of
those terms, and similar expressions that convey uncertainty of
future events or outcomes are intended to identify estimates,
projections and other forward-looking statements. Forward-looking
statements may include information concerning the Company’s ability
to position itself as a category leader and the ability to achieve
and maintain high growth. Additional factors that could cause
actual results to differ materially from those contemplated in this
press release can be found in the “Risk Factors” section of
Sientra’s public filings with the Securities and Exchange
Commission. All statements other than statements of historical fact
are forward looking statements. You are cautioned not to place
undue reliance on these forward-looking statements, and such
estimates, projections and other forward-looking statements speak
only as of the date they were made, and, except to the extent
required by law, the Company undertakes no obligation to update or
review any estimate, projection or forward-looking statement.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in the
Company’s business.
(*) Data on file
ContactInvestor Relations805-679-8885
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Apr 2023 to Apr 2024